US · Healthcare · Diagnostics & Research
EPS came in at 1.94 against a street estimate of 1.84 — a beat of 5.4%.
Analysts rate Danaher Corporation a strong buy (22 buy, 3 hold, 0 sell out of 25) with an average price target of $229.09.
| Fund | Stake |
|---|---|
| BlackRock Inc | 7.35% |
| Vanguard Capital Management, LLC | 5.85% |
| State Street Corp | 3.97% |
| FMR Inc | 3.21% |
| JPMorgan Chase & Co | 2.41% |
| Wellington Management Company LLP | 2.32% |
| Capital Research & Mgmt Co - Division 3 | 2.21% |
| T. Rowe Price Associates, Inc. | 2.18% |
| Document | Date |
|---|---|
| Board / officer change · Q3 2026 DANAHER CORPORATION - 8-K SUMMARY BUSINESS & SEGMENT HIGHLIGHTS • Julie Sawyer Montgomery appointed as President and CEO effective October 1, 2026, | 2026-08-03 |
| Quarterly report · Q2 2026 DANAHER CORPORATION – Q2 2026 10-Q SUMMARY HEADLINE NUMBERS • Six-month sales (ended June 26, 2026): $12,216 million vs. $11,677 million prior year | 2026-07-21 |
| Results announced · Q3 2026 DANAHER CORPORATION – Q2 2026 EARNINGS SUMMARY HEADLINE NUMBERS • Net earnings: $870 million, or $1.23 per diluted share, up 60% year-over-year • No | 2026-07-21 |
| Company announcement · Q2 2026 DANAHER CORPORATION - 8-K FILING SUMMARY HEADLINE NUMBERS • Total debt issuance: CHF 2,382,430,000 (~$2.6 billion USD equivalent) • Seven separate n | 2026-06-03 |
| Board / officer change · Q2 2026 DANAHER CORPORATION (DHR) - FORM 8-K SUMMARY HEADLINE NUMBERS • Annual shareholder meeting held May 5, 2026 • Omnibus Incentive Plan approved with 2 | 2026-05-07 |
| Quarterly report · Q1 2026 DANAHER CORPORATION - Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Total Sales: $5,951 million for Q1 2026 vs. $5,741 million for Q1 2025 (+3.7% year-ove | 2026-04-21 |
| Proxy statement · Q2 2026 DANAHER CORPORATION PROXY SUMMARY FOR RETAIL INVESTORS --- CEO TOTAL COMPENSATION & CHANGE Rainer M. Blair (President & CEO) 2025 Total Compensatio | 2026-03-25 |
| Annual report FY2025 DANAHER CORPORATION (DHR) — 2025 10-K SUMMARY HEADLINE NUMBERS • Shares Outstanding: 707.1 million shares as of February 2, 2026 • Market Cap (June | 2026-02-24 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Dividend | $0.40 / share ex-date Sep 30, 2026 · pay Oct 30, 2026 | 2026-09-30 |
| Dividend | $0.40 / share ex-date Jun 26, 2026 · pay Jul 31, 2026 | 2026-06-26 |
| Dividend | $0.40 / share ex-date Mar 27, 2026 · pay Apr 24, 2026 | 2026-03-27 |
| Dividend | $0.32 / share ex-date Dec 26, 2025 · pay Jan 30, 2026 | 2025-12-26 |
| Dividend | $0.32 / share ex-date Sep 26, 2025 · pay Oct 31, 2025 | 2025-09-26 |
| Split | 1128 : 1000 effective Oct 2, 2023 | 2023-10-02 |
| Announcement | Date |
|---|---|
| CEO to comment on 2025 financial performance at healthcare conference Danaher Corporation filed an 8-K on January 12, 2026, announcing that its CEO will comment on financial performance at the J.P. Morgan Healthcare Conference on January 13, 2026. The filing i | 2026-01-12 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Danaher Corporation — free to start.
Google PlayApp StoreData updated 2026-09-18.